Fifteen widely used medications- including two super-popular weight loss drugs – are part of Medicare’s next round of price negotiations, the federal government announced. The Department of Health and ...

Intel Corporation (INTC) shares surged 9.3% on takeover speculation following its CEO's December departure. Novo Nordisk A/S (NVO) shares fell 5.3% after Medicare included semaglutide, the key ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from cancer and type 2 diabetes to asthma.

Popular but pricey weight-loss drugs Ozempic and Wegovy are among the 15 medications whose prices will be subject to direct negotiations between Medicare and drug makers.

In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden adds Ozempic to list for Medicare price negotiationIn one of its last actions, the Biden ...

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...